|
|
|
06.05.26 - 22:49
|
LPKF Laser Aktie: Viel Zukunftsmusik eingepreist (Aktiencheck)
|
|
|
GarbsenKulmbach (www.aktiencheck.de) - LPKF Laser-Aktienanalyse von "Der Aktionär":
Michael Schröder vom Anlegermagazin "Der Aktionär" nimmt im Interview mit "Der Aktionär TV" die Aktie der LPKF Laser & Electronics SE (ISIN: DE0006450000, WKN: 645000, Ticker-Symbol: LPK, NASDAQ OTC-Symbol: LPKFF) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
06.05.26 - 22:36
|
Nebius Group Aktie: 655% in 13 Monaten! (Aktiencheck)
|
|
|
MoskauKulmbach (www.aktiencheck.de) - Nebius Group-Aktienanalyse von "Der Aktionär":
Alfred Maydorn vom Anlegermagazin "Der Aktionär" nimmt im Interview mit "Der Aktionär TV" die Aktie der Nebius Group N.V. (ISIN: NL0009805522, WKN: A1JGSL, Ticker-Symbol: YDX, NASDAQ-Symbol: NBIS) unter die Lupe.
Der Datacenter-Spezialist sei erst vor dreizehn Monaten zum Kauf empfohlen worden und liege schon jetzt mit satten 655% im Plus. [mehr]...
|
|
|
|
|
|
|
|
|
06.05.26 - 22:33
|
argenx to Present at BofA Securities 2026 Health Care Conference (GlobeNewswire EN)
|
|
|
May 6, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Executive Officer, will present at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 10:40 a.m. PT....
|
|
|
06.05.26 - 22:33
|
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights (Business Wire)
|
|
|
DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial (IST) Part 1a Expansion Cohort Enrolling, Updated Dataset Expected 2Q 2026
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpassed 70% of Required Interim Enrollment; Interim Analysis planned in 4Q 2026
$51.3 million in Cash, Cash Equivalents and Investments, Anticipated Runway through 2027
Conference Call and Webcast on May 7 at 8:00 AM ET / 7:00 AM CT
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026. Management will host a conference call on Thursday, May 7, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss the Company's business update and first quarter 2026 financial results.
“We continue to focus on moving our clinical programs forward. Looking ahe...
|
|
|
06.05.26 - 22:33
|
Orion S.A. Reports First Quarter Earnings; Increases Full Year 2026 Adjusted EBITDA Outlook (Business Wire)
|
|
|
HOUSTON--(BUSINESS WIRE)--Orion S.A. (NYSE: OEC), a specialty chemical company, today reported First Quarter 2026 Net sales of $460 million, a 4% decrease from the prior year, consisting of a 11% reduction in price, predominantly from the pass-through effect of lower year-over-year oil prices, and 1% adverse mix, which was partly offset by 2% higher volumes and 6% favorable foreign currency translation. Our first quarter results improved as the quarter progressed, despite a slow start in January and February which our Rubber segment's customers attributed to winter weather conditions. Demand picked up considerably during the month of March across both segments, particularly in our Specialty business.
For the quarter, Orion generated a consolidated Net loss of $10 million, and Adjusted EBITDA of $46 million. Working capital utilization is typically the highest in our first quarter, resulting in an Operating cash use of $12 million and free cash outflow of $48 million. Orion responded quickly to the March ...
|
|
|
|
|
|
|
06.05.26 - 22:18
|
Tronox Reports First Quarter 2026 Financial Results (PR Newswire)
|
|
|
STAMFORD, Conn., May 6, 2026 /PRNewswire/ -- Tronox Holdings plc (NYSE:TROX) ("Tronox" or the "Company"), the world's leading integrated manufacturer of titanium dioxide ("TiO2") pigment, today reported its financial results for the quarter ending March 31, 2026, as follows: First Quarter......
|
|
|
|
|
06.05.26 - 22:15
|
AIXTRON Aktie: Viel Zukunft bereits eingepreist (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - AIXTRON-Aktienanalyse von "Der Aktionär":
Michael Schröder vom Anlegermagazin "Der Aktionär" nimmt im Interview mit "Der Aktionär TV" die Aktie der AIXTRON SE (ISIN: DE000A0WMPJ6, WKN: A0WMPJ, Ticker-Symbol: AIXA, NASDAQ OTC-Symbol: AIXXF) unter die Lupe.
Die Nebenwerte zeigen würden aktuell eine deutlich stärkere Dynamik zeigen, getragen v.a. [mehr]...
|
|
|
|
|
06.05.26 - 22:12
|
How NASA′s Chief Plans to Bring Back the Moonwalk — And Beat China (Bloomberg)
|
|
|
On today's Big Take podcast, NASA Administrator Jared Isaacman sits down with Bloomberg's Tim Stenovec to talk about why the US needs to beat China to the moon, how he plans to vie with SpaceX and Blue Origin for top talent and what exactly he thinks alien life looks like. Listen to The Big Take podcast on Apple, Spotify or wherever you get your podcasts. (Source: Bloomberg)...
|
|
|
06.05.26 - 22:12
|
Autoliv Declares Quarterly Dividend (Cision)
|
|
|
(Auburn Hills, Michigan, USA, May 6, 2026) – Autoliv, Inc. (NYSE: ALV and SSE: ALIV.sdb), the worldwide leader in automotive safety systems, today announced that its Board of Directors has declared a quarterly dividend of 87 cents for the second quarter of 2026.
To holders of record on the close of business on Wednesday, May 20, the dividend will be payable on:
· Monday, June 8, 2026 to holders of Autoliv common stock listed on the New York Stock Exchange (Common Stock); and
· Tuesday, June 9, 2026 to holders of Autoliv Swedish Depository Receipts listed on Nasdaq Stockholm (SDRs)....
|
|
|
|
Alle News zu Europa 6037.3785 +2.76% (E.St.50 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
